6 results on '"Ugarte-Gil MF"'
Search Results
2. The Lupus Foundation of America-Rapid Evaluation of Activity in Lupus Clinician-Reported Outcome Predicts Damage in Patients With Systemic Lupus Erythematosus. Data From the Almenara Lupus Cohort.
- Author
-
Ugarte-Gil MF, Gamboa-Cárdenas RV, Reátegui-Sokolova C, Pimentel-Quiroz VR, Elera-Fitzcarrald C, Pastor-Asurza C, Rodriguez-Bellido Z, Perich-Campos R, and Alarcón GS
- Subjects
- Humans, Female, Male, Adult, Middle Aged, Cohort Studies, Predictive Value of Tests, Disease Progression, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic physiopathology, Lupus Erythematosus, Systemic epidemiology, Severity of Illness Index
- Abstract
Objective: To evaluate the predictive value of the LFA-REAL ClinRO (Lupus Foundation of America Rapid Evaluation of Activity in Lupus clinician-reported outcome) on damage accrual in systemic lupus erythematosus patients., Methods: Data from a prevalent lupus cohort were used. The LFA-REAL ClinRO includes 9 domains: mucocutaneous (global and 3 subdomains), musculoskeletal (global and 2 subdomains), cardiorespiratory, neuropsychiatric, renal, hematological, constitutional, vasculitis, and other (it allows for other or rare manifestations). For each domain, a 0- to 100-mm visual analog scale is used, and global domains are included except for the mucocutaneous and musculoskeletal domains where the subdomains are included; it allows for 3 manifestations under "other," so the score ranges from 0 to 1400 (sum of 14 in the visual analog scale). Damage was assessed with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index. Generalized estimating equations were performed, being the outcome the increase in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index; confounders from the previous visit were included; adjusted multivariable models were done. Incidence rate ratios per 10-unit increase in the LFA-REAL ClinRO were reported. Similar models were performed to evaluate the impact of the SLEDAI-2K (SLE Disease Activity Index) and physician global assessment on damage to determine which measure would better predict damage accrual., Results: Three-hundred thirty-one patients and 1425 visits were included, 1.9 (SD 1.2) years of follow-up. Disease duration at baseline was 10.7 (7.4) years. The mean LFA-REAL ClinRO was 18.2 (SD 30.7). During the follow-up visits, 63 (17.9%) patients accrued damage once; 4 (1.1%) accrued damage twice. The LFA-REAL ClinRO was predictive of damage accrual even after adjustment for possible confounders (incidence rate ratio 1.10 (95% confidence interval 1.04-1.16; p < 0.001). Similar results were obtained using the SLEDAI-2K and the physician global assessment., Conclusion: The LFA-REAL ClinRO is predictive of damage accrual, even after adjusting for possible confounders., Competing Interests: M.F.U.-G. has grant support from Janssen and Pfizer, has been speaker for GSK and AztraZeneca, and has been member of the advisory boards for AztraZeneca and Ferrer; R.V.G.-C. has grant support from Pfizer; C.R.-S. and V.R.P.-Q. have grant support from Janssen. The other authors declare no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
3. Age at diagnosis and health-related quality of life are associated with fatigue in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort.
- Author
-
Elera-Fitzcarrald C, Reátegui-Sokolova C, Gamboa-Cárdenas RV, Medina M, Zevallos F, Pimentel-Quiroz VR, Zeña-Huancas PA, Pastor-Asurza CA, Perich-Campos RA, Rodríguez-Bellido ZJ, Alarcón GS, and Ugarte-Gil MF
- Subjects
- Adult, Age Factors, Antimalarials therapeutic use, Cohort Studies, Cross-Sectional Studies, Fatigue complications, Female, Humans, Immunosuppressive Agents therapeutic use, Linear Models, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic drug therapy, Lupus Erythematosus, Systemic ethnology, Male, Middle Aged, Multivariate Analysis, Peru ethnology, Prednisone therapeutic use, Sex Factors, Surveys and Questionnaires, Treatment Outcome, Young Adult, Ethnicity psychology, Fatigue psychology, Lupus Erythematosus, Systemic psychology, Quality of Life psychology, Severity of Illness Index
- Abstract
Objective: To define the factors associated with fatigue in Mestizo patients with Systemic Lupus Erythematosus (SLE)., Methods: This is a cross-sectional study of SLE patients from a single center cohort. Visits were performed every six months. For these analyses, the first visit between October 2017 and December 2018 was included. Demographic and clinical characteristics as well as treatment were recorded at every visit. Fatigue was ascertained with the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-FT), Health-Related Quality of Life (HRQoL) with the LupusQoL, disease activity with the Systemic Lupus Erythematosus Disease Activity Index -2 K (SLEDAI-2K), and damage with the Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology damage index (SDI). Prednisone use was recorded as current daily dose. Immunosuppressive drugs and antimalarial use were recorded as current, past or never. Univariable and multivariable analyses were performed using linear regression models. For the multivariable analyses, model selection followed a backward elimination procedure., Results: Two hundred and twenty-six patients were evaluated. The mean (SD) age at diagnosis was 35.6 (13.1) years, 211 (93.4%) were female; and disease duration was 11.0 (7.3) years. The mean SLEDAI and SDI were 2.4 (3.5) and 1.3 (1.5), respectively. The mean FACIT-FT was 33.1 (10.8). On the multivariable analysis, age at diagnosis and some domains of HRQoL (physical health, emotional health and fatigue) remained associated., Conclusions: Age at diagnosis is negatively associated with fatigue whereas HRQoL domains like physical health, emotional health and fatigue are positively associated with fatigue.
- Published
- 2020
- Full Text
- View/download PDF
4. Better Health-Related Quality of Life in Systemic Lupus Erythematosus Predicted by Low Disease Activity State/Remission: Data From the Peruvian Almenara Lupus Cohort.
- Author
-
Ugarte-Gil MF, Gamboa-Cárdenas RV, Reátegui-Sokolova C, Medina-Chinchón M, Zevallos F, Elera-Fitzcarrald C, Pimentel-Quiroz V, Cucho-Venegas JM, Rodríguez-Bellido Z, Pastor-Asurza CA, Alarcón GS, and Perich-Campos R
- Subjects
- Adolescent, Adult, Cohort Studies, Female, Humans, Immunosuppressive Agents therapeutic use, Lupus Erythematosus, Systemic drug therapy, Lupus Erythematosus, Systemic ethnology, Male, Middle Aged, Peru ethnology, Prednisone therapeutic use, Remission Induction, Surveys and Questionnaires, Treatment Outcome, Young Adult, Ethnicity psychology, Lupus Erythematosus, Systemic psychology, Quality of Life, Severity of Illness Index
- Abstract
Objective: To determine if low disease activity state (LDAS)/remission predicts a better health-related quality of life (HRQoL)., Methods: Patients with systemic lupus erythematosus from a single center and having completed at least 2 visits were included. Visits were performed every 6 months. HRQoL was measured with the LupusQoL questionnaire. The definition of remission included a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of 0, prednisone daily dosage of ≤5 mg/day, and immunosuppressive drugs on maintenance dose. LDAS was defined as a SLEDAI-2K score of ≤4, prednisone daily dosage of ≤7.5 mg/day, and immunosuppressive drugs as maintenance therapy. For these analyses, remission and LDAS were combined as one variable. Generalized estimating equations were calculated, using as the outcome 1 of each of the 8 components of the LupusQoL questionnaire in the subsequent visit and the activity state in the previous visit. Multivariable models were adjusted for possible confounders., Results: A total of 243 patients were included. During the follow-up, 590 visits (61.6%) were categorized as LDAS/remission. LDAS/remission predicted a better HRQoL in the components of physical health (B = 4.17 [95% confidence interval (95% CI) 1.20, 7.14]; P = 0.006), pain (B = 6.47 [95% CI 3.18, 9.76]; P < 0.001), planning (B = 4.97 [95% CI 1.43, 8.52]; P = 0.006), burden to others (B = 4.12 [95% CI 0.24, 8.01]; P = 0.037], emotional health (B = 4.50 [95% CI 1.56, 7.44]; P = 0.003), and fatigue (B = 3.25 [95% CI 0.04, 6.47]; P = 0.048)., Conclusion: Being in LDAS/remission predicts a better HRQoL, especially in the components of physical health, pain, planning, burden to others, emotional health, and fatigue., (© 2019, American College of Rheumatology.)
- Published
- 2020
- Full Text
- View/download PDF
5. Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort.
- Author
-
Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, Quintana R, Gómez-Puerta JA, Catoggio LJ, Alvarellos A, Saurit V, Borba E, Sato E, Costallat L, Da Silva NA, Iglesias-Gamarra A, Neira O, Reyes-Llerena G, Cardiel MH, Amigo MC, Acevedo-Vásquez E, Esteva-Spinetti MH, Alarcón GS, and Pons-Estel BA
- Subjects
- Adult, Age Factors, Antimalarials therapeutic use, Female, Follow-Up Studies, Humans, Latin America epidemiology, Latin America ethnology, Lupus Erythematosus, Systemic ethnology, Lupus Erythematosus, Systemic physiopathology, Male, Prognosis, Racial Groups, Remission Induction, Treatment Outcome, Young Adult, Immunosuppressive Agents therapeutic use, Lupus Erythematosus, Systemic drug therapy, Lupus Erythematosus, Systemic epidemiology, Prednisone therapeutic use, Severity of Illness Index
- Abstract
Objective: To determine the predictors of remission and low disease activity state (LDAS) in patients with systemic lupus erythematosus (SLE)., Methods: Three disease activity states were defined: Remission = SLE Disease Activity Index (SLEDAI) = 0 and prednisone ≤ 5 mg/day and/or immunosuppressants (maintenance dose); LDAS = SLEDAI ≤ 4, prednisone ≤ 7.5 mg/day and/or immunosuppressants (maintenance dose); and non-optimally controlled state = SLEDAI > 4 and/or prednisone > 7.5 mg/day and/or immunosuppressants (induction dose). Antimalarials were allowed in all groups. Patients with at least 2 SLEDAI reported and not optimally controlled at entry were included in these analyses. Outcomes were remission and LDAS. Multivariable Cox regression models (stepwise selection procedure) were performed for remission and for LDAS., Results: Of 1480 patients, 902 were non-optimally controlled at entry; among them, 196 patients achieved remission (21.7%) and 314 achieved LDAS (34.8%). Variables predictive of a higher probability of remission were the absence of mucocutaneous manifestations (HR 1.571, 95% CI 1.064-2.320), absence of renal involvement (HR 1.487, 95% CI 1.067-2.073), and absence of hematologic involvement (HR 1.354, 95% CI 1.005-1.825); the use of immunosuppressive drugs before the baseline visit (HR 1.468, 95% CI 1.025-2.105); and a lower SLEDAI score at entry (HR 1.028, 95% CI 1.006-1.051 per 1-unit decrease). These variables were predictive of LDAS: older age at entry, per 5-year increase (HR 1.050, 95% CI 1.004-1.098); absence of mucocutaneous manifestations (HR 1.401, 95% CI 1.016-1.930) and renal involvement (HR 1.344, 95% CI 1.049-1.721); and lower SLEDAI score at entry (HR 1.025, 95% CI 1.009-1.042)., Conclusion: Absence of mucocutaneous, renal, and hematologic involvement, use of immunosuppressive drugs, and lower disease activity early in the course of the disease were predictive of remission in patients with SLE; older age was predictive of LDAS.
- Published
- 2019
- Full Text
- View/download PDF
6. Treat to target in systemic lupus erythematosus: a commentary.
- Author
-
Ugarte-Gil MF, Burgos PI, and Alarcón GS
- Subjects
- Antimalarials therapeutic use, Humans, Immunosuppressive Agents therapeutic use, Prednisone therapeutic use, Quality of Life, Treatment Outcome, Lupus Erythematosus, Systemic therapy, Remission Induction methods, Severity of Illness Index
- Abstract
Treat to target (T2T) strategies have proved to be useful in several chronic disorders, including Rheumatoid Arthritis. In systemic lupus erythematosus (SLE), T2T strategy has been proposed in order to control disease activity, improve health-related quality of life, and reduce morbidity and mortality. Remission would be the main target, but a low disease activity state (LDAS) could be an acceptable alternative. However, due to SLE protean manifestations, the operational definitions of both remission and LDAS are still in progress. The definitions of these targets, remission and LDAS, should include a validated disease activity index, the treatments allowed, and the minimum length of time the target should be maintained. Furthermore, achieving these targets should result in better disease outcomes such as reducing damage accrual. This review addresses the current state regarding these possible targets in SLE and the impact of achieving them in intermediate and long-term outcomes of this disease.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.